| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.03. | Sunshine Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.02. | Sunshine Biopharma: Vorstand erhält Ermächtigung für Reverse Split | 2 | Investing.com Deutsch | ||
| 20.02. | Sunshine Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | Sunshine Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.12.25 | Sunshine Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10.25 | Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada | 427 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that... ► Artikel lesen | |
| SUNSHINE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 28.10.25 | Sunshine Biopharma stock rises after Health Canada approval for Domperidone | 3 | Investing.com | ||
| 28.10.25 | Sunshine Biopharma-Aktie legt nach Zulassung für Domperidon in Kanada zu | 3 | Investing.com Deutsch | ||
| 28.10.25 | Sunshine Biopharma subsidiary receives Health Canada approval for drug | 2 | Investing.com | ||
| 28.10.25 | Sunshine Biopharma: Tochtergesellschaft erhält kanadische Zulassung für Domperidon | 1 | Investing.com Deutsch | ||
| 28.10.25 | Sunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea | 323 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions... ► Artikel lesen | |
| 20.10.25 | Sunshine Biopharma Inc.: Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline | 399 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions... ► Artikel lesen | |
| 16.10.25 | Sunshine Biopharma stock soars after launch of cholesterol drug Pravastatin | 1 | Investing.com | ||
| 16.10.25 | Sunshine Biopharma Inc.: Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin | 371 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 16, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety... ► Artikel lesen | |
| 14.10.25 | Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy | 318 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and... ► Artikel lesen | |
| 14.10.25 | Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution | 587 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to... ► Artikel lesen | |
| 14.10.25 | Sunshine Biopharma approves $5M strategic bitcoin investment | 4 | Seeking Alpha | ||
| 14.10.25 | Sunshine Biopharma approves $5 million Bitcoin investment | 3 | Investing.com | ||
| 14.10.25 | Sunshine Biopharma Inc.: Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience | 249 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines in a... ► Artikel lesen | |
| 09.10.25 | Sunshine Biopharma Inc.: Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections | 280 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,385 | -0,21 % | Aktien Frankfurt Ausblick: Stabilisierung - Unicredit bietet für Commerzbank | FRANKFURT (dpa-AFX) - Der Dax dürfte recht stabil in den elften Handelstag seit Kriegsausbruch im Iran starten. Der X-Dax signalisierte für den deutschen Leitindex rund eine Stunde vor Handelsbeginn... ► Artikel lesen | |
| GILEAD SCIENCES | 118,32 | -0,12 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| AURORA CANNABIS | 2,800 | -0,88 % | K-Tech Solutions Company Limited Announces Joint Venture with Aurora AZ Energy Ltd. to Develop up to 500 MW of AI and HPC Infrastructure in Canada | HONG KONG and NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- K-Tech Solutions Company Limited (Nasdaq: KMRK) ("K-Tech" or the "Company"), a technology firm specializing in high-performance computing infrastructure... ► Artikel lesen | |
| ABBVIE | 178,80 | +0,56 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| CANOPY GROWTH | 0,835 | 0,00 % | Cannabis-Boom 2026: Warum Bioxyne und Canopy jetzt das Spielfeld in Deutschland besetzen | ||
| ELI LILLY | 782,30 | -0,29 % | Stammzelltherapien erreichen den Markt - Mesoblast neben Eli Lilly und Novartis im Fokus | ||
| ASTRAZENECA | 159,15 | +0,19 % | BERENBERG stuft ASTRAZENECA auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Astrazeneca mit einem Kursziel von 17000 Pence auf "Buy" belassen. Die Ziele für den operativen Cashflow des Pharmakonzerns... ► Artikel lesen | |
| TILRAY BRANDS | 5,360 | -0,37 % | Tilray Brands, Inc.: Tilray Brands Enters Agreement to Acquire BrewDog's Key U.S. Assets, Expanding Its U.S. Craft Beer Platform | NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 49,750 | +0,35 % | EQS-News: Evotec SE: Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer klinischen Studie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer... ► Artikel lesen | |
| TEVA | 24,700 | -0,80 % | Teva Pharmaceutical Industries Ltd: Teva Releases Q1 2026 Aide Memoire | TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its... ► Artikel lesen | |
| ABBOTT LABORATORIES | 91,80 | +0,44 % | Abbott to close $21B Exact Sciences deal on March 23 | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| DERMAPHARM | 40,900 | -0,73 % | Ihre wichtigsten Termine: Nvidia, Qualcomm, Audi, Dermapharm, Docusign und Fraport stehen heute im Fokus! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland: Fraport... ► Artikel lesen | |
| BIOTEST | 31,800 | 0,00 % | Biotest erhält FDA-Zulassung | Summary: FDA lässt Fibrinogen-Produkt für den US-Markt zu Biotest entwickelt und produziert, Grifols vermarktet Markteinführung für 2026 geplant Pipeline gewinnt strategisch an Gewicht Biotest hat einen... ► Artikel lesen | |
| MPH HEALTH CARE | 18,200 | -2,41 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen |
Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.11.2025 / 12:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |